Literature DB >> 30108840

Synthesis, structure-activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase.

Fanxun Zeng1, Tiantian Qi2, Chunyan Li1, Tingfang Li1, Honglin Li2, Shiliang Li1,2, Lili Zhu2, Xiaoyong Xu1,3.   

Abstract

A series of 4-thiazolidinone derivatives were synthesized and evaluated as novel human dihydroorotate dehydrogenase (hDHODH) inhibitors. Compounds 26 and 31 displayed IC50 values of 1.75 and 1.12 μM, respectively. The structure-activity relationship was summarized. Further binding mode analysis revealed that compound 31 could form a hydrogen bond with Tyr38 and a water-mediated hydrogen bond with Ala55, which may be necessary for maintaining the bioactivities of the compounds in this series. Further structural optimization of the para- or meta-position of the phenyl group at R will lead to the identification of more potent hDHODH inhibitors.

Entities:  

Year:  2017        PMID: 30108840      PMCID: PMC6071797          DOI: 10.1039/c7md00081b

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  26 in total

1.  HRCT-proven leflunomide pneumonitis in a patient with psoriatic arthritis and normal lung function tests and chest radiography.

Authors:  Martin A Lee; David G Hutchinson
Journal:  Rheumatology (Oxford)       Date:  2010-02-08       Impact factor: 7.580

Review 2.  4-Thiazolidinones: the advances continue….

Authors:  Avinash C Tripathi; Shiv Ji Gupta; Gul Naz Fatima; Pankaj Kumar Sonar; Amit Verma; Shailendra K Saraf
Journal:  Eur J Med Chem       Date:  2013-11-27       Impact factor: 6.514

3.  Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.

Authors:  Phaedra Eleftheriou; Athina Geronikaki; Dimitra Hadjipavlou-Litina; Paola Vicini; Olga Filz; Dmitry Filimonov; Vladimir Poroikov; Shailendra S Chaudhaery; Kuldeep K Roy; Anil K Saxena
Journal:  Eur J Med Chem       Date:  2011-10-25       Impact factor: 6.514

4.  Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.

Authors:  David B Sykes; Youmna S Kfoury; François E Mercier; Mathias J Wawer; Jason M Law; Mark K Haynes; Timothy A Lewis; Amir Schajnovitz; Esha Jain; Dongjun Lee; Hanna Meyer; Kerry A Pierce; Nicola J Tolliday; Anna Waller; Steven J Ferrara; Ashley L Eheim; Detlef Stoeckigt; Katrina L Maxcy; Julien M Cobert; Jacqueline Bachand; Brian A Szekely; Siddhartha Mukherjee; Larry A Sklar; Joanne D Kotz; Clary B Clish; Ruslan I Sadreyev; Paul A Clemons; Andreas Janzer; Stuart L Schreiber; David T Scadden
Journal:  Cell       Date:  2016-09-15       Impact factor: 41.582

5.  Original 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as inhibitors of human dihydroorotate dehydrogenase (DHODH).

Authors:  Hélène Munier-Lehmann; Marianne Lucas-Hourani; Sandrine Guillou; Olivier Helynck; Gigliola Zanghi; Anne Noel; Frédéric Tangy; Pierre-Olivier Vidalain; Yves L Janin
Journal:  J Med Chem       Date:  2015-01-06       Impact factor: 7.446

6.  5-Arylidene-4-thiazolidinone derivatives active as antidegenerative agents on human chondrocyte cultures.

Authors:  Annamaria Panico; Rosanna Maccari; Venera Cardile; Lucia Crasci; Simone Ronsisvalle; Rosaria Ottanà
Journal:  Med Chem       Date:  2013-02       Impact factor: 2.745

7.  Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.

Authors:  K R Herrlinger; M Diculescu; K Fellermann; H Hartmann; S Howaldt; R Nikolov; A Petrov; W Reindl; J M Otte; S Stoynov; U Strauch; A Sturm; R Voiosu; A Ammendola; B Dietrich; B Hentsch; E F Stange
Journal:  J Crohns Colitis       Date:  2012-10-16       Impact factor: 9.071

8.  Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.

Authors:  Margaret A Phillips; Ramesh Gujjar; Nicholas A Malmquist; John White; Farah El Mazouni; Jeffrey Baldwin; Pradipsinh K Rathod
Journal:  J Med Chem       Date:  2008-06-04       Impact factor: 7.446

9.  Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Authors:  J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

10.  The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.

Authors:  Edmond F O'Donnell; Prasad Rao Kopparapu; Daniel C Koch; Hyo Sang Jang; Jessica Lynne Phillips; Robert L Tanguay; Nancy I Kerkvliet; Siva Kumar Kolluri
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.